At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Influence of Vorapaxar on Thrombin Generation and Coagulability
In Brief
A Phase 4 clinical trial evaluating Vorapaxar, Vorapaxar and Aspirin, and 2 other interventions for Coronary Artery Disease and 2 related conditions. Completed, enrolled 81 participants across 1 site.
Detailed Summary
This investigation will be conducted in patients 18-75 years of age with multiple coronary artery disease risk factors (antiplatelet naïve patients) and patients with prior MI or PVD on antiplatelet therapy. Pharmacodynamics will be assessed at multiple time points to assess onset-, maintenance-, and offset-effect of vorapaxar on thrombin generation, platelet reactivity, and plasma/platelet endothelial and inflammatory biomarkers. Safety assessment will be assessed throughout the study.
Study Details
Timeline
Interventions
Vorapaxar is the principle study drug and will be given to all subjects.
Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.